| Purity | ≥99% |
| Molecular Weight | 5,135.9 Da |
| Category | GHRH analog / Growth hormone-releasing factor (GRF) analog |
| Sequence | N-(trans-3-hexenoyl)-[Tyr¹]-hGRF(1–44) amide — a 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoyl modification (CAS 218949-48-5) |
TESA
A growth-hormone-releasing peptide explored in research for its potential to reduce stubborn visceral (belly) fat and support metabolic health.
Starting from $55.00
| Qty | Per vial | Discount |
|---|---|---|
| 1 | $55.00 | — |
| 2 | $50.60 | 8% off |
| 4 | $48.40 | 12% off |
| 8 | $45.65 | 17% off |
| 12 | $42.90 | 22% off |
For research use only. Not for human consumption.
Storage Conditions
Store lyophilized powder at −20 °C. After reconstitution, store at 4 °C and use within 28 days. Avoid repeated freeze-thaw cycles.
Overview
TESA is a growth-hormone-releasing peptide studied for targeting visceral fat — the deep abdominal fat around the organs — by prompting the body to release its own growth hormone in natural pulses, rather than supplying growth hormone directly.
Commonly Studied For
- Visceral (belly) fat reduction
- Liver-fat and metabolic research
- Natural growth-hormone and IGF-1 support
- Body-composition research models
Research use only. This product is intended for in vitro and laboratory research purposes only. It is not approved by the FDA for human or veterinary use. It is not a drug, food, or cosmetic, and may not be misbranded, misused, or sold for purposes other than research.
All information provided is for research and educational purposes only and does not constitute medical advice.